ResMed Inc. vs Standard Lithium Ltd — how do they compare? ResMed Inc. trades at $230.96 (market cap $31.89B), while Standard Lithium Ltd trades at $1.63 (market cap $398.07M). The key difference: ResMed Inc. is far larger — about 80.1× Standard Lithium Ltd's market cap, and ResMed Inc. pays a 1.16% dividend while Standard Lithium Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold ResMed Inc. for 51 Days and Standard Lithium Ltd for 23 Days on average.
| RMD | SLI | |
|---|---|---|
Market Cap | $31.89B | $398.07M |
Volume | 618,314 | 1,564,155 |
Sector | Health | Basic Materials |
52-Week High | $277.88 | $5.65 |
52-Week Low | $182.82 | $1.61 |
Typical Hold Time | 51 Days | 23 Days |
Enterprise Value | $31.24B | $260.98M |
Dividend Yield | 1.16% | — |
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $230.91, up 2.18% today, with a bullish technical signal and strong fundamentals. The company reported consistent earnings beats in recent quarters, with Q3 2026 EPS expected at $2.68. Revenue grew to $5.15B in 2025, with a net income margin of 26.94%. Analyst consensus is a buy, with a $242.70 price target. Recent news highlights EPS growth targets of 12%-14% and participation in investor conferences.
Outlook is positive due to robust earnings growth and market share gains, but risks include competitive pressures and regulatory investigations. The stock offers upside to the consensus target, supported by institutional buying and solid cash flow generation.
Standard Lithium (SLI) trades at $1.615, down 2.12% today, with a bearish technical signal despite oversold RSI readings. The company shows negative profitability with ROE at -15.55% and no revenue in 2025, but has achieved key project milestones including customer offtake agreements with LG Energy Solution and Trafigura. Analyst consensus remains strongly bullish with a $3.83 price target, reflecting optimism about the Arkansas lithium project's 2026 final investment decision.
The investment case hinges on successful execution of the South West Arkansas lithium project, which could transform SLI from development to production phase. Key risks include project delays, funding requirements, and lithium price volatility. With 100% analyst buy ratings and institutional backing from BlackRock and Amundi, the stock offers high-risk, high-reward potential for investors betting on North American lithium production growth.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →Standard Lithium Ltd. is a company focused on the development of lithium projects in North America, with a primary focus on extracting lithium from brine resources. Their flagship projects aim to utilize proprietary, advanced direct lithium extraction (DLE) technologies to produce high-purity lithium compounds in an environmentally responsible manner. The company seeks to become a key domestic supplier to the growing electric vehicle and battery storage markets.
Read more on SLI →